| 4.62 -0.36 (-7.23%) | 08-28 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.05 | 1-year : | 6.58 |
| Resists | First : | 5.18 | Second : | 5.63 |
| Pivot price | 4.77 |
|||
| Supports | First : | 4.44 | Second : | 3.69 |
| MAs | MA(5) : | 4.93 |
MA(20) : | 4.78 |
| MA(100) : | 4.19  |
MA(250) : | 5.15 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 36.6 |
D(3) : | 44.1 |
| RSI | RSI(14): 44.5 |
|||
| 52-week | High : | 11.45 | Low : | 1.07 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ RZLT ] has closed above bottom band by 28.0%. Bollinger Bands are 23.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.95 - 4.99 | 4.99 - 5.01 |
| Low: | 4.52 - 4.55 | 4.55 - 4.58 |
| Close: | 4.57 - 4.62 | 4.62 - 4.67 |
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Sat, 22 Aug 2026
Rezolute, Inc.'s (NASDAQ:RZLT) Shift From Loss To Profit - simplywall.st
Thu, 20 Aug 2026
Balyasny Asset Management L.P. Reduces Stake in Rezolute Inc (RZ - GuruFocus
Wed, 12 Aug 2026
Bank of America Corp (RZLT) discloses 1.2% Rezolute ownership in 13G/A - Stock Titan
Tue, 21 Jul 2026
Rezolute Management to Meet Investors Online July 28-29 - Stock Titan
Thu, 25 Jun 2026
RZLT Forecast — Price Target — Prediction for 2027 - TradingView
Mon, 15 Jun 2026
Guggenheim raises Rezolute stock price target on trial outlook - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 96 (M) |
| Shares Float | 60 (M) |
| Held by Insiders | 10.1 (%) |
| Held by Institutions | 98.3 (%) |
| Shares Short | 16,880 (K) |
| Shares Short P.Month | 16,410 (K) |
| EPS | -0.82 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.12 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -48.8 % |
| Return on Equity (ttm) | -81.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.9 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -73 (M) |
| Levered Free Cash Flow | -44 (M) |
| PE Ratio | -5.71 |
| PEG Ratio | 0 |
| Price to Book value | 4.12 |
| Price to Sales | 0 |
| Price to Cash Flow | -6.06 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|